Ken Griffin Citadel Advisors
Ken Griffin founded Citadel, one of the world’s largest and most successful hedge funds. Starting his trading career from his Harvard dorm room at a young age, Griffin quickly developed a keen sense for markets and built Citadel into a global powerhouse with billions in assets under management. Known for his quantitative and technology-driven strategies, Griffin has also made headlines for significant philanthropic contributions, supporting causes in education, the arts, and public institutions. Over the years, he has earned recognition as one of the preeminent figures in modern finance.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$615M |
| 2 |
Uber
UBER
|
+$551M |
| 3 |
Expedia Group
EXPE
|
+$523M |
| 4 |
PayPal
PYPL
|
+$452M |
| 5 |
Eaton
ETN
|
+$408M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$681M |
| 2 |
RTN
Raytheon Company
RTN
|
+$543M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$537M |
| 4 |
Charter Communications
CHTR
|
+$472M |
| 5 |
SPDR Gold Trust
GLD
|
+$464M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 5.29% |
| 2 | Financials | 4.55% |
| 3 | Industrials | 4.18% |
| 4 | Healthcare | 4.08% |
| 5 | Consumer Discretionary | 3.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
8151
Ovid Therapeutics
OVID
$528M
| $158K | ﹤0.01% |
+38,088
| New | +$120K |
|
8152
SEACOR Marine Holdings
SMHI
$268M
| $158K | ﹤0.01% |
+11,459
| New | +$149K |
|
|
AXU
8153
DELISTED
Alexco Resource Corp
AXU
| $157K | ﹤0.01% |
67,618
-34,885
| -34% | -$64.3K |
|
|
VER
8154
CALL
DELISTED
VEREIT, Inc.
VER
| $157K | ﹤0.01% |
3,400
-3,660
| -52% | -$175K |
|
8155
PUT
Calumet Specialty Products
CLMT
$4.19B
| $156K | ﹤0.01% |
42,800
-77,900
| -65% | -$269K |
|
8156
Verastem
VSTM
$596M
| $156K | ﹤0.01% |
9,681
+260
| +3% | +$3.74K |
|
|
CRCM
8157
PUT
DELISTED
CARE.COM, INC.
CRCM
| $156K | ﹤0.01% |
10,400
-42,600
| -80% | -$511K |
|
8158
PUT
Kura Oncology
KURA
$964M
| $155K | ﹤0.01% |
+11,300
| New | +$167K |
|
8159
PUT
Novavax
NVAX
$1.33B
| $155K | ﹤0.01% |
38,900
+23,700
| +156% | +$103K |
|
8160
Rambus
RMBS
$10.9B
| $155K | ﹤0.01% |
11,244
-474,357
| -98% | -$6.37M |
|
8161
PUT
Syndax Pharmaceuticals
SNDX
$1.77B
| $155K | ﹤0.01% |
17,700
-65,800
| -79% | -$483K |
|
|
MAAS
8162
Maase Inc
MAAS
$7.37B
| $155K | ﹤0.01% |
+414
| New | +$137K |
|
|
ADMS
8163
DELISTED
Adamas Pharmaceuticals
ADMS
| $155K | ﹤0.01% |
41,154
+8,553
| +26% | +$40.9K |
|
|
CYOU
8164
PUT
DELISTED
Changyou.com Limited American Depositary Share
CYOU
| $155K | ﹤0.01% |
15,800
-2,400
| -13% | -$23.1K |
|
|
CHU
8165
DELISTED
China Unicom (HONG KONG) Limited
CHU
| $155K | ﹤0.01% |
16,561
+2,793
| +20% | +$26.8K |
|
|
ONCY
8166
Oncolytics Biotech
ONCY
$99.5M
| $154K | ﹤0.01% |
32,465
+15,549
| +92% | +$17.6K |
|
|
ACHN
8167
PUT
DELISTED
Achillion Pharmaceuticals
ACHN
| $154K | ﹤0.01% |
25,600
-4,200
| -14% | -$24.3K |
|
|
LUNA
8168
DELISTED
Luna Innovations Incorporated
LUNA
| $154K | ﹤0.01% |
+21,036
| New | +$139K |
|
8169
Arbutus Biopharma
ABUS
$924M
| $153K | ﹤0.01% |
+54,993
| New | +$89K |
|
8170
ProShares Ultra Euro
ULE
$4.43M
| $153K | ﹤0.01% |
+11,092
| New | +$150K |
|
|
CBAY
8171
CALL
DELISTED
Cymabay Therapeutics
CBAY
| $153K | ﹤0.01% |
78,300
-52,600
| -40% | -$198K |
|
|
AUTL
8172
Autolus Therapeutics
AUTL
$572M
| $152K | ﹤0.01% |
+11,541
| New | +$151K |
|
|
NGD
8173
PUT
DELISTED
New Gold Inc
NGD
| $152K | ﹤0.01% |
172,900
-127,100
| -42% | -$115K |
|
8174
Rayonier Advanced Materials
RYAM
$570M
| $152K | ﹤0.01% |
39,519
-31,976
| -45% | -$131K |
|
|
UNIT
8175
Uniti Group
UNIT
$2.43B
| $152K | ﹤0.01% |
18,475
-259,190
| -93% | -$1.88M |
|
Similar funds
Ken Griffin's Q4 2019 Portfolio in Review
As of Q4 2019, Ken Griffin held 10,299 positions worth $230B, up 8.7% from $212B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Ken Griffin withdrew a net $8.18B in Q4 2019, closing 1,266 positions and reducing 4,117 holdings. Its most notable exit was Celgene Corp, an estimated $681M position sold in full.
By sector, the portfolio is most concentrated in Technology at 5.3% of assets, down from 5.4% a quarter earlier, followed by Financials and Industrials.
Against the trend, Ken Griffin opened a new position in Interxion Holding N.V. worth $83.9M.
- Ken Griffin's largest Q4 2019 buy was Interxion Holding N.V.: 1,000,931 shares worth $83.9M.
- Ken Griffin added most to Amazon in Q4 2019, an estimated $615M increase.
- Ken Griffin's biggest Q4 2019 reduction was Raytheon Company, cutting an estimated $543M.
- Ken Griffin fully exited Celgene Corp in Q4 2019, selling an estimated $681M.
- Ken Griffin's ten largest holdings make up 23% of its $230B portfolio in Q4 2019.
- Ken Griffin opened 1,220 new positions and closed 1,266 in Q4 2019.
- Ken Griffin's portfolio value rose 8.7% quarter-over-quarter to $230B.
Based on Citadel Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.